Si Chen
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Shenyang Pharmaceutical University (2022); Shanghai University (2024–2025); Guangzhou University of Chinese Medicine (2020); Union Hospital (2025); United States Food and Drug Administration (2013–2025); Southwest University (2022–2024); University of Miami (2015); Xidian University (2018–2019); Harbin Medical University (2014); University of Illinois Urbana-Champaign (2014); Sun Yat-sen University (2019–2025); Jinan University (2006–2011); Duke University (2021); Xuzhou Medical College (2022–2024); Second Military Medical University (2017); German Cancer Research Center (2019); Shenzhen University (2025); Baylor College of Medicine (2021); Capital Medical University (2016–2019); University of Milan (2021); Jilin University (2018–2022); Anhui Medical University (2015); Chinese Academy of Medical Sciences & Peking Union Medical College (2016); Hong Kong University of Science and Technology (2018); Peking University (2017–2018); University of Macau (2016–2021); Nankai University (2012–2015); Heidelberg University (2019); National Medical Products Administration (2022–2024); Sichuan University (2024); Biochemical Society (2025); Liaoning University of Traditional Chinese Medicine (2021); Peking Union Medical College Hospital (2016); Tianjin Medical University General Hospital (2022); Shantou University (2021); University of Florida (2023); Wuhan University (2011–2023); Xinyang Agriculture and Forestry University (2023); Soochow University (2014); Applied Optronics (United States) (2016–2019); Sun Yat-sen Memorial Hospital (2025); Huaian First People’s Hospital (2025); Key Laboratory of Guangdong Province (2020–2021); BeiGene (China) (2019); Nanjing Drum Tower Hospital (2021); Wuhan Business University (2023); First Affiliated Hospital of Shantou University Medical College (2021); Maine Farmland Trust (2021); Beijing Anzhen Hospital (2016); First Hospital of Jilin University (2018–2022); Duke Medical Center (2021); Shanghai East Hospital (2022); University of Kansas Medical Center (2021); The First Affiliated Hospital, Sun Yat-sen University (2023); Anhui Provincial Hospital (2015); Miami Heart Research Institute (2015); Chinese Academy of Agricultural Sciences (2019–2024); Renmin Hospital of Wuhan University (2021–2023); China XD Group (China) (2018); Sun Yat-sen University Cancer Center (2022); Beijing Friendship Hospital (2019); Tianjin Municipal Research Institute for Family Planning (2014); Food and Drug Administration (2024–2025); Erasmus MC Cancer Institute (2017); Ministry of Agriculture and Rural Affairs (2021–2022); Duke University Hospital (2021); Ningbo University Affiliated Hospital (2017); Tumor Hospital of Guangxi Medical University (2020); Ministry of Education (2016); Children's Hospital of Chongqing Medical University (2024); Henan Institute of Science and Technology (2024–2025); Union Hospital (2024); Huazhong University of Science and Technology (2024–2025); China Agricultural University (2012); City University of Macau (2021); East China Normal University (2020); Harbin Veterinary Research Institute (2019); Nanjing Medical University (2013–2025); Chongqing Medical University (2024); University of Hong Kong (2018); Northwest A&F University (2017); China Medical University (2022); Florida College (2023)
Faculty Researcher
Upstream record may be merged OpenAlex, the source of these figures, lists 85 institutions in 10 countries for this author record — a pattern that usually means it combines several researchers with similar names. The totals above may include work by other people.
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Si Chen's research focuses on understanding the mechanisms underlying disease and the potential therapeutic effects of various compounds. A significant portion of their work investigates cellular processes, including apoptosis and mitochondrial function, particularly in the context of cardiac health and diabetes. Chen has explored the protective mechanisms of compounds like lupeol against cardiac hypertrophy and the role of specific proteins, such as USP28, in mitigating cardiac dysfunction. Their research also delves into the complexities of cancer, examining chemotherapy resistance in colorectal cancer stem cells and exploring the role of tumor-associated macrophages in immune evasion. Additionally, Chen has investigated the genotoxicity of compounds like luteolin, studying how metabolic enzymes influence these effects.
Metrics
- h-index: 40
- Publications: 191
- Citations: 4,885
Selected Publications
-
Corrigendum to “Characterizing the metabolites of the tyrosine-kinase inhibitor pexidartinib in mouse feces, urine, plasma, and liver” [J. Pharm. Biomed. Anal. 265 (2025) 117034] (2026)
-
Translating in vitro mechanistic findings to in vivo toxicity outcomes: A case study of Usnic acid hepatotoxicity (2026)
-
Potential anticancer effects and toxicity of flavones luteolin and apigenin <i>in vivo</i> (2025)
-
Characterizing the metabolites of the tyrosine-kinase inhibitor pexidartinib in mouse feces, urine, plasma, and liver (2025)
-
Development of a TK6-derived cell line expressing four human cytochrome P450s for genotoxicity testing (2025)
-
7-Hydroxycannabidiol and 7-carboxycannabidiol induced cytotoxicity via apoptosis and endoplasmic reticulum stress in human hepatic cells (2025)
-
Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells (2025)
-
Metabolism and liver toxicity of cannabidiol (2024)
-
Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cells (2024)
-
Use of Lentivirus‐Based Method for Establishing TK6 Human Cell Lines Expressing Cytochrome P450 and its Applications in Genotoxicity Testing (2024)
-
Evaluation of weak genotoxicity of hydroxychloroquine in human TK6 cells (2024)
-
Induction of apoptosis by cannabidiol and its main metabolites in human Leydig cells (2023)
-
The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib (2023)
-
Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays (2023)
Collaboration Network
Top Collaborators
- The genotoxicity potential of luteolin is enhanced by CYP1A1 and CYP1A2 in human lymphoblastoid TK6 cells
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells
Showing 5 of 15 shared publications
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells
- Metabolism and liver toxicity of cannabidiol
- Induction of apoptosis by cannabidiol and its main metabolites in human Leydig cells
Showing 5 of 11 shared publications
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells
- Induction of apoptosis by cannabidiol and its main metabolites in human Leydig cells
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
Showing 5 of 9 shared publications
- The genotoxicity potential of luteolin is enhanced by CYP1A1 and CYP1A2 in human lymphoblastoid TK6 cells
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
- The expression of Phase II drug-metabolizing enzymes in human B-lymphoblastoid TK6 cells
Showing 5 of 9 shared publications
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells
- Induction of apoptosis by cannabidiol and its main metabolites in human Leydig cells
- Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cells
- Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells
- Induction of apoptosis by cannabidiol and its main metabolites in human Leydig cells
- Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cells
- Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells
- Metabolism and liver toxicity of cannabidiol
- Toxicity of cannabidiol and its metabolites in TM3 mouse Leydig cells: a comparison with primary human Leydig cells
- The genotoxicity potential of luteolin is enhanced by CYP1A1 and CYP1A2 in human lymphoblastoid TK6 cells
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- Evaluation of weak genotoxicity of hydroxychloroquine in human TK6 cells
- Actein contributes to black cohosh extract‐induced genotoxicity in human TK6 cells
- Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
- Study of the roles of cytochrome P450 (CYPs) in the metabolism and cytotoxicity of perhexiline
- Corrigendum to “Characterizing the metabolites of the tyrosine-kinase inhibitor pexidartinib in mouse feces, urine, plasma, and liver” [J. Pharm. Biomed. Anal. 265 (2025) 117034]
- Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
- Actein contributes to black cohosh extract‐induced genotoxicity in human TK6 cells
- Development of a TK6-derived cell line expressing four human cytochrome P450s for genotoxicity testing
- Metabolism and liver toxicity of cannabidiol
- Comparing the cannabidiol-induced transcriptomic profiles in human and mouse Sertoli cells
- Potential anticancer effects and toxicity of flavones luteolin and apigenin <i>in vivo</i>
- Development of a TK6-derived cell line expressing four human cytochrome P450s for genotoxicity testing
- The genotoxicity potential of luteolin is enhanced by CYP1A1 and CYP1A2 in human lymphoblastoid TK6 cells
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
- Development of a TK6-derived cell line expressing four human cytochrome P450s for genotoxicity testing
- Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice
- The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib
- Study of the roles of cytochrome P450 (CYPs) in the metabolism and cytotoxicity of perhexiline
- Evaluation of weak genotoxicity of hydroxychloroquine in human TK6 cells
- Actein contributes to black cohosh extract‐induced genotoxicity in human TK6 cells
- Development of a TK6-derived cell line expressing four human cytochrome P450s for genotoxicity testing
- Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
- Metabolism and liver toxicity of cannabidiol
Similar Researchers
Based on overlapping research topics